Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Maju Mathews,Srihari Gopal,Arun Singh,Isaac Nuamah,Katalin Pungor,Wilson Tan,Bernardo Soares,Edward Kim,Adam J Savitz
DOI: https://doi.org/10.2147/NDT.S221242
IF: 2.989
2020-06-20
Neuropsychiatric Disease and Treatment
Abstract:Maju Mathews, 1 Srihari Gopal, 2 Arun Singh, 3 Isaac Nuamah, 4 Katalin Pungor, 5 Wilson Tan, 6 Bernardo Soares, 7 Edward Kim, 8 Adam J Savitz 2 1 Global Medical Affairs, Janssen Research & Development, LLC, Titusville, NJ, USA; 2 Department of Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA; 3 Department of Neuroscience, Janssen Research & Development, LLC, Pennington, PA, USA; 4 Clinical Biostatistics, Janssen Research & Development, LLC, Titusville, NJ, USA; 5 Medical Affairs, Janssen-Cilag GmbH, Neuss, North Rhine-Westphalia, Germany; 6 Regional Medical Affairs, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore; 7 Medical Affairs, Jan-Cil, High Wycombe, Buckinghamshire, UK; 8 Janssen Scientific Affairs, Janssen Scientific Affairs, LLC, Titusville, NJ, USA Correspondence: Maju Mathews Global Medical Affairs, Janssen Research & Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, USA Tel +1 609 433-9257 Email mmathe20@its.jnj.com Background: Sudden discontinuation from antipsychotic treatment is a common occurrence in patients with schizophrenia. Lower rates of relapse could be expected for patients discontinuing treatment from longer-acting formulations vs their shorter-acting equivalents. Objective: To compare relapse rates and time-to-relapse between the active (analogous to adherent patients) and placebo (analogous to non-adherent patients in the real-world) arms of three different formulations of paliperidone (oral paliperidone extended release [paliperidone ER], paliperidone palmitate once monthly [PP1M], and paliperidone palmitate three monthly [PP3M] long-acting injectables). Methods: Data from three similarly designed, randomized relapse prevention studies in adult patients with schizophrenia were analyzed. Results: In total, 922 patients were included (active treatment: 473, placebo: 449). Lowest percentage of patients experienced relapse with PP3M PP1M (172 days [134– 222 days])> paliperidone ER (58 days [42– 114 days]) and was "not-estimable" in the active treatment group due to low relapse rates. Hazard ratios (HR) of the three paliperidone formulations relative to their respective placebos were PP3M ([HR: 3.81; 95% CI: 2.08, 6.99; P PP1M [HR: 3.60; 95% CI: 2.45, 5.28; P paliperidone ER [HR: 2.83; 95% CI: 1.73, 4.63; P< 0.001]). Conclusion: The lower percentage of relapse during active treatment and longer time to relapse after discontinuing active treatment with longer-duration antipsychotic formulations suggests the benefit of longer-acting over shorter-acting formulations, especially in patients susceptible to poor adherence. Clinical trial registration: paliperidone ER (NCT00086320), PP1M (NCT00111189), and PP3M (NCT01529515). Keywords: relapse prevention, schizophrenia, oral paliperidone extended release, paliperidone palmitate once monthly, paliperidone palmitate three monthly
psychiatry,clinical neurology